Barbara Ann Karmanos Cancer Institute
The goal of this clinical trial is to: * In Phase 1 (observational) to develop an algorithm for treatment of Duffy-null positive patients for chemotherapy dosing * In Phase 2 (interventional), use the algorithm created in phase 1 to adjust chemotherapy dosing for Duffy-null patients
Inclusion Criteria: * Participant must self-identify as being of Middle Eastern or African descent. * Participant must be diagnosed with histologically or cytologically confirmed solid organ cancer and be treatment naive. * Melanoma is allowed; sarcoma is not eligible. * Secondary malignancies are allowed. * Participants who have received only surgery alone as treatment are eligible * Participant must be between the ages of 18-80. * Participant or their legally authorized representative (LAR) must be able to understand a written informed consent document and be willing to sign it. Exc…
Standard of care chemotherapy for solid tumor malignancies with dose adjustment according to the algorithm produced in phase 1 for Duffy-null positive patients
Standard of care chemotherapy for solid tumor malignancies with dose modifications and delays according to the standard of care using CTCAE criteria.
Arctuva estimate
Verify or correct the compensation shown for this listing.